Riasi 2015.

Methods	Study design: unclear (awaiting information from the authors) Setting: neurology clinic of Vali Asr Hospital of Birjand
Participants	Details of sampling frame: Total n analysed = 40 participants (wrists) Gender distribution: Total: 10 males, 30 females Age: 32.75 ± 4.33 years (ranging from 20 to 48 years) Duration of CTS symptoms: CTS diagnosis confirmed based on clinical examinations (Phalen’s and Tinel’s sign) and a proximal and distal amplitude difference higher than 50% and delayed distal motor conduction velocity lower than 20 m/s Inclusion criteria: Personal consent of the participants  Participants must not be pregnant at the time of entering the study, and their condition must not be the result of maternity and pregnancy Participant’s CTS should not be a complication of tumours in the carpal region or a result of trauma or fracture to the carpal bones Participant should not have suffered from the cellular damage of the upper limb or their spine before entering the study Participants must not have any history of substance abuse No signs of denervation should come up in the EMG scan results of the participants. Also, their condition should not have led to other complications such as thenar atrophy Participant's condition must not be the result of rheumatoid arthritis or other collagen vascular disorders  The participant's condition must not be the result of metabolic disorders such as diabetes or disorders of the thyroid gland  Participants must be conscious to a degree which enables them to partake in follow‐up studies and comply with their physicians’ necessary recommendations Exclusion criteria: Absence in follow‐up re‐examinations and clinical tests Specific organic pathological disorders such as cancers, tumours, fractures, and collagen vascular diseases such as rheumatoid arthritis, metabolic diseases such as diabetes, thyroid disorders, or other problems that may be disruptive in the study process
Interventions	Group 1: ibuprofen (800 mg twice daily for 4‐6 weeks) with a short wrist splint Group 2: ibuprofen (800 mg twice daily for 4‐6 weeks)
Outcomes	Outcomes evaluated at baseline and after 4 to 6 weeks of treatment NCV and EMG examinations
Notes	Email sent to the authors, awaiting response. Unclear if randomised trial or not